Figure 3
Figure 3. Rapamycin is required for Treg induction. Flt3L alone or with antigen fails to induce Treg. (A) Induction of OVA-specific CD4+CD25+FoxP3+ Treg cells in DO11.10-tg Rag-2−/− BALB/c mice treated with Flt3L/OVA323-339/rapamycin combination. Mice treated with OVA323-339, Flt3L, Flt3L/OVA323-339, or rapamycin only failed to generate Treg (n = 3-5 per group). Statistical differences were determined by 1-way ANOVA with Bonferonni’s multiple comparison posttest analysis. All groups tested were significantly different from the Flt3L/OVA323-339/Rapa treatment group (P < .0001). (B) Representative examples of stains for CD25 and FoxP3 (gated off CD4+ cells) for naïve controls, Flt3L-treated, rapamycin-treated, and Flt3L/OVA323-339/rapamycin-treated mice. (C) Expression of CTLA-4, Helios, CD62L, and GITR molecules in the induced Treg. Data are average ± SD (n = 5 per group).

Rapamycin is required for Treg induction. Flt3L alone or with antigen fails to induce Treg. (A) Induction of OVA-specific CD4+CD25+FoxP3+ Treg cells in DO11.10-tg Rag-2−/− BALB/c mice treated with Flt3L/OVA323-339/rapamycin combination. Mice treated with OVA323-339, Flt3L, Flt3L/OVA323-339, or rapamycin only failed to generate Treg (n = 3-5 per group). Statistical differences were determined by 1-way ANOVA with Bonferonni’s multiple comparison posttest analysis. All groups tested were significantly different from the Flt3L/OVA323-339/Rapa treatment group (P < .0001). (B) Representative examples of stains for CD25 and FoxP3 (gated off CD4+ cells) for naïve controls, Flt3L-treated, rapamycin-treated, and Flt3L/OVA323-339/rapamycin-treated mice. (C) Expression of CTLA-4, Helios, CD62L, and GITR molecules in the induced Treg. Data are average ± SD (n = 5 per group).

Close Modal

or Create an Account

Close Modal
Close Modal